However, I think it was a strategic mistake setting expectations so high,” he said. New trial Martin Holst Lange, Novo ...

Despite these setbacks, Novo Nordisk said it remains committed to CagriSema ... both semaglutide and cagrilintide in ...

A phase 3 trial of Novo Nordisk’s next-generation obesity ... 25% on calls with investors throughout 2023 and 2024. Martin Holst Lange, executive vice president of development at Novo, repeated ...

Novo Nordisk’s shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90bn off the valuation of Europe’s largest company by market capitalisation.

This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement Friday.

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and ... in monotherapy,” Martin Holst Lange, executive vice president ...

we plan to further explore the additional weight loss potential of CagriSema," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. The company stated: "The results ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli ... in monotherapy,” Martin Holst Lange, executive vice president for ...

Novo Nordisk egen forventning var 25 procent, lød det fra forskningschef Martin Holst Lange for to år siden, skriver det svenske nyhedsbureau Direkt. I marts nedjusterede Novo så de forventninger til ...

This was achieved even though only 57% of patients reached the highest CagriSema dose," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. "With the insights ...